2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-146379
    SARS-CoV-2-IN-19 2244991-17-9 98%
    SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of SARS-CoV-2 with an EC50 of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases.
    SARS-CoV-2-IN-19
  • HY-146381
    SARS-CoV-2-IN-20 1260244-33-4 98%
    SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of SARS-CoV-2 with an EC50 of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases.
    SARS-CoV-2-IN-20
  • HY-146394
    HBV-IN-22 2338573-94-5 98%
    HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively.
    HBV-IN-22
  • HY-146395
    HBV-IN-23 2413649-89-3 98%
    HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC50 of 0.58 μM. HBV-IN-23 inhibits HBV DNA replication in both agent sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells apoptosis.
    HBV-IN-23
  • HY-146400
    Antibacterial agent 97 1714961-61-1 98%
    Antibacterial agent 97 (hit compound) is a potent antibacterial agent. Antibacterial agent 97 shows antibacterial activities with MIC of 16 and 16 µg/mL for Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus), respectively.
    Antibacterial agent 97
  • HY-146403
    Antibacterial agent 98 2408695-41-8 98%
    Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus).
    Antibacterial agent 98
  • HY-146417
    Antiviral agent 19 1807887-16-6 98%
    Antiviral agent 19 (Compound 3) is a selective inhibitor against Zika virus infection with an EC50 of 1.3 µM. Antiviral agent 19 has low cytotoxicity.
    Antiviral agent 19
  • HY-146418
    Antiviral agent 20 2407570-07-2 98%
    Antiviral agent 20 (Compound 17b) is a selective inhibitor against Zika virus infection with an EC50 of 4.5 µM. Antiviral agent 20 has low cytotoxicity.
    Antiviral agent 20
  • HY-146426
    MraY-IN-2 98%
    MraY-IN-2 (compound 6) is a potent MurNAc-pentapeptide translocase (MraY) inhibitor with an IC50 value of 4.5 μM. MraY-IN-2 can be used for researching anti-bacteria.
    MraY-IN-2
  • HY-146427
    Antifungal agent 29 98%
    Antifungal agent 29 (compound 9d) is a potent, selective and non-toxic antifungal agent. Antifungal agent 29 shows antifungal activity towards Cryptococcus neoformans (MIC ≤ 0.23 μM).
    Antifungal agent 29
  • HY-146428
    Anti-MRSA agent 4 98%
    Anti-MRSA agent 4 (compound 7a) is a potent and selective growth inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA), with MIC ≤ 0.26 µM. Anti-MRSA agent 4 exhibits no cytotoxic and no hemolytic activity in HEK293 cells.
    Anti-MRSA agent 4
  • HY-146447
    PXYC13 1031940-69-8 98%
    PXYC13 is a ribosomal protein S1 (RpsA) antagonist with Kds of 7.61 and 8.50 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
    PXYC13
  • HY-146448
    PXYD3 2680554-46-3 98%
    PXYD3 is a ribosomal protein S1 (RpsA) antagonist with Kds of 5.66 and 6.91 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
    PXYD3
  • HY-146449
    PXYD4 2712534-78-4 98%
    PXYD4 is a ribosomal protein S1 (RpsA) antagonist with Kds of 3.24 and 1.64 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
    PXYD4
  • HY-14644B
    Apilimod hydrochloride 870087-37-9 98%
    Apilimod (STA 5326) hydrochloride is a PIKFYVE kinase inhibitor that promotes NLRP3 inflammatory vesicle activation and IL-1β secretion. Apilimod hydrochloride has been shown to inhibit host cell proteases, which may prevent viral invasion but also block antiviral immune responses, potentially exacerbating immunosuppression in COVID-19.
    Apilimod hydrochloride
  • HY-146450
    PXYC2 865101-22-0 98%
    PXYC2 is a ribosomal protein S1 (RpsA) antagonist with Kds of 6.35 and 5.11 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
    PXYC2
  • HY-146451
    PXYC12 1112415-91-4 98%
    PXYC12 is a ribosomal protein S1 (RpsA) antagonist with Kds of 2.67 and 4.67 μM for RpsA-CTD and RpsA-CTD Δ438A, respectively. RpsA plays an important role in the trans-translation process of Mycobacterium Tuberculosis (Mtb).
    PXYC12
  • HY-146458
    Antibacterial agent 102 2413293-65-7 98%
    Antibacterial agent 102 (compound 32) possesses potent in vitro and in vivo antibacterial activity, with MICs < 0.5 μg/mL in Staphylococcus aureus (S. aureus). Antibacterial agent 102 also moderately inhibits CYP3A4 with an IC50 value of 6.148 μM. Antibacterial agent 102 can reduce Methicillin-resistant Staphylococcus aureus (MRSA) load in thigh infected mice.
    Antibacterial agent 102
  • HY-146463
    NusB-IN-1 2923738-92-3 98%
    NusB-IN-1 (Compound 22r) is a potent, orally active bacterial rRNA synthesis inhibitor. NusB-IN-1 shows antimicrobial activity against MRSA and VRSA. NusB-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NusB-IN-1
  • HY-146464
    Antifungal agent 30 2422019-91-6 98%
    Antifungal agent 30 (compound A18) is a potent antifungal agent. Antifungal agent 30 shows excellent antifungal activity against Candida albicans (CPCC400616) and Aspergillus fumigatus, with MIC of 0.03 and 0.5 μg/mL, respectively. Antifungal agent 30 also shows excellent antifungal activity against fluconazole-resistant strains. The potent antifungal activity of Antifungal agent 30 mainly causes by hydrogen and coordination bond interaction with the CYP51.
    Antifungal agent 30
Cat. No. Product Name / Synonyms Application Reactivity